Allogene Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Allogene Therapeutics, Inc. (ALLO) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $20.39 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-12
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $20.39M.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21.64M.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $22.99M.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $24.31M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $20.39M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $21.64M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $22.99M 10-K · filed 2026-03-12 |
| 2025-09-30 | $24.31M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $25.65M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $27.02M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $28.41M 10-K · filed 2025-03-13 |
| 2024-09-30 | $29.83M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $31.33M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $32.75M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $33.26M 10-K · filed 2024-03-14 |
| 2023-09-30 | $34.74M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $36.24M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $37.77M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $39.31M 10-K/A · filed 2024-03-14 |
| 2022-09-30 | $40.88M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $42.47M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $33.13M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $34.28M 10-K · filed 2022-02-23 |
| 2021-09-30 | $28.92M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $30.06M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $31.20M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $32.31M 10-K · filed 2021-02-25 |
| 2020-09-30 | $33.50M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $34.31M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $34.74M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $35.92M 10-K · filed 2020-02-27 |
| 2019-09-30 | $17.76M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $18.52M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $19.33M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |